Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.1 g/mol
PuubChem: CID 16131447
CAS Number: 386264-39-7
What is AOD9604 peptide?
AOD9604 is a modified peptide originally developed for the treatment of obesity. It is a modification of the peptide fragment 176-191 of human growth hormone (HGH). Interestingly, the mode of action of AOD9604 is restricted to promoting lipolysis in the body making it a popular choice for the treatment of obesity. The peptide does not affect levels of insulin or IGF1 in the body. Therefore, the use of AOD9604 does not trigger a clinical risk of developing either diabetes or intolerance towards glucose. Further, being structurally similar to HGH, it does not induce immunogenic reactions and is immunologically safe.
Research related to AOD 9604
AOD9604 and Obesity
AOD9604 has been brought into the clinical trials with the objective of targeting obesity using a peptide similar to HGH. Phase IIb clinical trials conducted on 300 obese individuals in Australia has shown that when administered once daily, the peptide has resulted in consistent weight loss over a period of 12 weeks. The rate of weight reduction in patients undergoing treatment has been thrice compared to the placebo cohort and weight loss has been steady over the entire study period. This observation indicated that the peptide is unlikely to generate resistance and thus continued treatment would result in pronounced effect.
Researchers have worked on mice models to explore the underlying mechanism of action of AOD9604. Initial hypothesis has proposed that AOD9604 binds and activates β-3-adrenergic receptors which are present on the surface of white adipose tissues. Upon binding to the cognate receptors, the peptide triggers downstream signaling which mobilizes the fat cells from storage mode to usable state by enhancing the rate of metabolism. Interestingly, mice which are genetically mutated in β-3-adrenergic receptors also have undergone fat loss possibly through apoptosis of the white adipose tissues.
AOD9604 and Cardiac Disease
AOD9604 improves cardiac health indirectly by mobilizing fat and reducing obesity. The peptide thus reduces the chances of cardiac disease caused by obesity. Interestingly, apart from its principal function of decreasing the fat burden in the body, there are other mechanisms by which the drug improves cardiac conditions. These pathways are independent of β-3-adrenergic receptors and contribute towards the improvement of general metabolism, leading to improved cardiac health. Drugs are often known to induce various independent positive effects on the body. Some drugs such as acipimox and piogitazone are known to improve metabolism without having any direct influence on fat reduction.
Joint Pain and Function
Improvement of cartilage growth has always been a persistent clinical challenge. Studies involving AOD9-604 have demonstrated that it helps to address this issue. Researches have shown that upon introduction of the peptide directly into arthritic joints in rats, it improves pain management, decrease in movement disability and enhances general quality of life. AOD 9604 has the capacity to promote growth of cartilage tissue in the arthritic joints but the effect is pronounced in conjunction with other existing therapies. Both clinical examination and microscopic cartilage structure analysis in the affected joints have shown positive results upon AOD9604 treatment of osteoarthritis. This highlights that application of this peptide can be beneficial in both prevention and treatment of the above condition.
The peptide shows consistently minimal adverse effects and high bioavailability in the subcutaneous region of mice. However, the dosage administered to mice (per kg) cannot be scaled up for human administration. At present, its availability at Biotech Peptides is restricted only for academic and research use and not for clinical human administration.
Only buy AOD9604 peptide if you are a licensed researcher.